Literature DB >> 16111772

HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype.

Elisabetta Prat1, Utano Tomaru, Lidia Sabater, Deric M Park, Rebekah Granger, Niels Kruse, Joan M Ohayon, Maria P Bettinotti, Roland Martin.   

Abstract

The HLA region, and particularly the DR15 haplotype (containing the two DRB* genes DRB1*1501 and DRB5*0101 and the tightly linked DQ alleles DQA*0102 and DQB1*0602, which together form the DQw6 molecule) in Caucasians, shows the strongest genetic association with multiple sclerosis (MS). In the DR15 haplotype, two beta-chains HLA-DRB1*1501 and -DRB5*0101 are co-expressed resulting in two different surface HLA-DR alphabeta heterodimers, DR2b and DR2a. Most previous studies focused on DRB1*1501, however, both DR2a and DR2b may contribute to MS pathogenesis via antigen presentation to myelin-specific T lymphocytes. We therefore analyzed the expression of the two DR15 genes in various antigen presenting cells (APCs), central nervous system and thymic tissues. Transcript levels were higher for DRB5*0101 in all cell types and tissues. Both HLA-DR heterodimers were expressed at significant levels on the cell surface, where they showed a differential expression pattern in different APCs. They were similarly regulated after stimulation with interferon-gamma and interleukin-4. Finally, immunohistochemistry experiments indicated that both molecules were expressed in thymic tissue. Our results encourage future research to investigate the potential functional relevance of both genes for the pathogenesis of MS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16111772     DOI: 10.1016/j.jneuroim.2005.04.027

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  22 in total

1.  Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice.

Authors:  Kazuyuki Kawamura; Katherine A McLaughlin; Robert Weissert; Thomas G Forsthuber
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

Review 2.  Advancing drug delivery systems for the treatment of multiple sclerosis.

Authors:  Inna Tabansky; Mark D Messina; Catherine Bangeranye; Jeffrey Goldstein; Karen M Blitz-Shabbir; Suly Machado; Venkatesh Jeganathan; Paul Wright; Souhel Najjar; Yonghao Cao; Warren Sands; Derin B Keskin; Joel N H Stern
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

3.  Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.

Authors:  Lisa E Creary; Kalyan C Mallempati; Sridevi Gangavarapu; Stacy J Caillier; Jorge R Oksenberg; Marcelo A Fernández-Viňa
Journal:  Mult Scler       Date:  2018-04-23       Impact factor: 6.312

4.  Complete nucleotide sequence characterization of DRB5 alleles reveals a homogeneous allele group that is distinct from other DRB genes.

Authors:  Konstantinos Barsakis; Farbod Babrzadeh; Anjo Chi; Kalyan Mallempati; William Pickle; Michael Mindrinos; Marcelo A Fernández-Viña
Journal:  Hum Immunol       Date:  2019-04-05       Impact factor: 2.850

Review 5.  Revealing the genetic basis of multiple sclerosis: are we there yet?

Authors:  Sergio E Baranzini
Journal:  Curr Opin Genet Dev       Date:  2011-01-17       Impact factor: 5.578

6.  Absence of the tag polymorphism for the risk haplotype HLA-DR2 for multiple sclerosis in Wixárika subjects from Mexico.

Authors:  G V González-Enríquez; B M Torres-Mendoza; J Márquez-Pedroza; M A Macías-Islas; G G Ortiz; J A Cruz-Ramos
Journal:  Immunogenetics       Date:  2018-02-03       Impact factor: 2.846

7.  Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Authors:  Rosa Faner; Eddie James; Laurie Huston; Ricardo Pujol-Borrel; William W Kwok; Manel Juan
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

8.  Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis.

Authors:  Jacqueline A Quandt; Jaebong Huh; Mirza Baig; Karen Yao; Naoko Ito; Mark Bryant; Kazuyuki Kawamura; Clemencia Pinilla; Henry F McFarland; Roland Martin; Kouichi Ito
Journal:  J Immunol       Date:  2012-08-10       Impact factor: 5.422

9.  Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis.

Authors:  Stacy J Caillier; Farren Briggs; Bruce A C Cree; Sergio E Baranzini; Marcelo Fernandez-Viña; Patricia P Ramsay; Omar Khan; Walter Royal; Stephen L Hauser; Lisa F Barcellos; Jorge R Oksenberg
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

10.  Analysis of HLA DR2&DQ6 (DRB1*1501, DQA1*0102, DQB1*0602) haplotypes in Iranian patients with multiple sclerosis.

Authors:  Mojdeh Ghabaee; Asghar Bayati; Shahla Amri Saroukolaei; Mohamad Ali Sahraian; Mohammad Hosein Sanaati; Parisa Karimi; Massoud Houshmand; Homa Sadeghian; Leila Hashemi Chelavi
Journal:  Cell Mol Neurobiol       Date:  2008-08-26       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.